Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.75 USD | +0.66% | +1.54% | +0.83% |
Apr. 18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Apr. 18 | Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.76B |
---|---|---|---|---|---|
Net income 2024 * | -456M | Net income 2025 * | -551M | EV / Sales 2024 * | - |
Net cash position 2024 * | 619M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-17.2
x | P/E ratio 2025 * |
-15.2
x | Employees | 334 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.17% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | +0.66% | ||
1 week | +1.54% | ||
Current month | +1.14% | ||
1 month | +1.14% | ||
3 months | +1.76% | ||
6 months | +87.09% | ||
Current year | +0.83% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 43 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Deval Patrick
BRD | Director/Board Member | 67 | 21-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 42.75 | +0.66% | 714,167 |
24-04-26 | 42.47 | +0.95% | 680,906 |
24-04-25 | 42.07 | +0.41% | 691,659 |
24-04-24 | 41.9 | -0.21% | 629,646 |
24-04-23 | 41.99 | -0.26% | 1,390,239 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.83% | 7.76B | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.62% | 22.18B | |
-16.67% | 21.2B | |
-8.86% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CERE Stock